Nebenwirkungen · Capecitabine Teva
Capecitabine Teva 150 mg film-coated tablets Capecitabine Teva 500 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 16–17
HOS-215431 · Präparat HOS-155434
16 Body System Very Common Common Rare/Very Rare (Post-Marketing All grades All grades Experience) + Blood and lymphatic Neutropenia, Bone marrow + system disorders Leucopenia, depression, +Febrile + Anaemia, Neutropenia + Neutropenic fever, Thrombocytopenia Immune system - Hypersensitivity disorders Metabolism and Appetite decreased Hypokalaemia, nutrition disorders Hyponatraemia, Hypomagnesaemia, Hypocalcaemia, Hyperglycaemia Psychiatric disorders - Sleep disorder, Anxiety Nervous system Paraesthesia, Neurotoxicity, Tremor, disorders Dysaesthesia, Neuralgia, Peripheral neuropathy, Hypersensitivity Peripheral sensory reaction, Hypoaesthesia neuropathy, Dysgeusia, Headache Eye disorders Lacrimation increased Visual disorders, Dry eye, Eye pain, Visual impairment, Vision blurred Ear and labyrinth - Tinnitus, Hypoacusis disorders Cardiac disorders - Atrial fibrillation, Cardiac ischaemia/infarction Vascular disorders Lower limb oedema, Flushing, Hypotension, Hypertension, Hypertensive crisis, + Embolism and Hot flush, Phlebitis thrombosis Respiratory, thoracic Sore throat, Hiccups, and mediastinal system Dysaesthesia pharynx Pharyngolaryngeal disorders pain, Dysphonia Gastrointestinal Constipation, Upper gastrointestinal disorders Dyspepsia haemorrhage, Mouth ulceration, Gastritis, Abdominal distension, Gastroesophageal reflux disease, Oral pain, Dysphagia, Rectal haemorrhage, Abdominal pain lower, Oral dysaesthesia, Paraesthesia oral, Hypoaesthesia oral, Abdominal discomfort Hepatobiliary - Hepatic function disorders abnormal Skin and subcutaneous Alopecia, Nail disorder Hyperhidrosis, Rash tissue disorders erythematous, Urticaria, Night sweats
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T15:40:00Z · SHA-256 360b33238effee7033c9ecfa3731a36e172b67d4837e971f09a6e80d5cda73df · Passage 63df8fb7fcb9e55f07fcf916ba373c01b4e52908f3cf5214a5aa264cfdb759ce · Zeichen 17558–21476 im Abschnitt